Essa Pharmaceuticals Corporation
Executive Vice President of R and D
Texas Bioalliance Feb 2011 - Mar 2014
President
Pivotal Biosciences Feb 2011 - Mar 2014
Member Board of Directors
Transgeneron Therapeutics Jan 2009 - Jul 2009
Vice President Preclinical Development Part-Time
Cossum Consulting Jan 2009 - Jul 2009
President
Education:
University of Tasmania 1980 - 1984
Doctorates, Doctor of Philosophy, Toxicology, Pharmacology
Skills:
Biotechnology Drug Discovery Drug Development Clinical Development Oncology Clinical Trials Life Sciences Pharmaceutical Industry Regulatory Affairs Cancer
Robert F. Rando - Beaconsfield, CA Michael E. Hogan - The Woodlands TX Thomas L. Wallace - The Woodlands TX Paul A. Cossum - The Woodlands TX
Assignee:
Aronex Pharmaceuticals, Inc. - The Woodlands TX Baylor College of Medicine - Houston TX
International Classification:
A61K 3170
US Classification:
514 44
Abstract:
Guanosine-rich oligonucleotides having sequences that favor the formation under physiological conditions of a stable four-stranded structure containing two stacked guanosine quartets (G4s) are disclosed. These oligonucleotides demonstrate enhanced nuclease resistance, cellular uptake and biological efficacy. Methods and composition for treating viral infection using these guanosine-rich oligonucleotides are also disclosed. Certain embodiments of the new oligonucleotides are 16-17 nucleotides long and contain at least one C-5 propynyl dU substitution. A method for designing anti-viral oligonucleotides is also disclosed.